Last updated: February 28, 2026
What is FABIOR?
FABIOR (tildrakizumab-asmn) is a monoclonal antibody approved for plaque psoriasis treatment. It targets interleukin-23 (IL-23), reducing inflammation and immune response. Approved by the U.S. FDA in 2018, it is marketed by Sun Pharmaceutical Industries.
What Role Do Excipients Play in FABIOR?
Excipients support drug stability, bioavailability, administration, and patient compliance. For biologics like FABIOR, excipient selection influences shelf life, injection stability, and immunogenicity.
What Are the Key Excipient Components in FABIOR?
Biologics like FABIOR generally contain excipients such as:
- Sugars (e.g., sucrose): Stabilize protein structure during freeze-thaw cycles, lyophilization, or liquid storage.
- Aqueous buffers (e.g., histidine, phosphate buffers): Maintain optimal pH, preserving protein stability.
- Non-ionic surfactants (e.g., polysorbate 80): Minimize aggregation and surface adsorption.
- Stabilizers (e.g., polysorbates): Ensure long-term stability against denaturation.
Detailed formulation data for FABIOR is proprietary, but biologics with similar mechanisms commonly incorporate these excipients.
How Does Excipient Strategy Impact Commercial Opportunities?
Enhancing Formulation Stability
Robust formulations extend product shelf life, improve transportation logistics, and reduce manufacturing costs. Stability increases allow for wider distribution and shelf availability, opening markets in countries with stringent storage conditions.
Differentiation Through Bioavailability
Excipients influence injection bioavailability. Optimized formulations can improve patient experience via reduced injection volume or frequency, impacting market uptake.
Cost Optimization and Manufacturing Efficiency
Using excipients that simplify manufacturing processes, require minimal handling, and enable lyophilization reduces costs and increases supply chain reliability.
Intellectual Property and Patent Expansion
Formulation patents focusing on novel excipient combinations can extend product exclusivity, delaying generic competition.
Meeting Regulatory and Market Standards
Custom excipients can reduce immunogenicity and adverse reactions, facilitating approval in complex markets with strict safety standards.
What Are the Commercial Opportunities for Excipient Innovation?
Development of Next-Generation Stabilizers
Innovating with new stabilizers or surfactants can improve shelf life and reduce immunogenic reactions, attracting partnerships with biosimilar or generic developers.
Formulation Optimization for Self-Administered Delivery
Creating formulations suitable for pre-filled syringes with lower injection volumes and enhanced stability expands market adoption, especially in outpatient settings.
Lyophilized Formulations for Specialty Markets
Lyophilized formulations with enhanced excipient profiles improve room-temperature stability, reducing cold chain dependence and expanding access in emerging markets.
Platform Technologies for Broad Biologic Application
Developing excipient platforms applicable across multiple biologics can generate licensing income and reduce formulation development timeline.
Custom Excipients for Reduced Immunogenicity
Novel excipients that minimize immune responses can differentiate products, enabling premium pricing strategies and expanding market share.
Limitations and Challenges
- Regulatory hurdles: New excipients face lengthy approval pathways, especially for biologics.
- Scale-up complexities: Some novel excipients may introduce manufacturing risks.
- Cost considerations: Introducing new excipients increases R&D and approval costs, with uncertain market returns.
Summary of Formulation Considerations
| Excipients |
Function |
Impact on Commercial Opportunity |
| Sucrose |
Stabilizes proteins during storage |
Extends shelf life, broadens distribution |
| Histidine buffer |
Maintains pH stability |
Enhances stability and reduces degradation |
| Polysorbate 80 |
Minimizes aggregation |
Improves injection quality and safety |
Key Takeaways
- Excipients are critical in stabilizing biologics like FABIOR, directly influencing product shelf life, safety, and patient experience.
- Strategic excipient selection enables formulation improvements, cost reductions, and regulatory advantages.
- Innovation in excipient technology supports market differentiation, expanded access, and new delivery methods.
- Patent protections on novel excipient compositions can extend product lifecycle and generate licensing opportunities.
- Developing platform excipient technologies offers broader commercial potential across multiple biologics.
FAQs
1. Can excipient modifications improve FABIOR's stability?
Yes, optimizing excipient compositions can enhance stability, reduce degradation, and extend shelf life.
2. Are there alternative excipients to polysorbate 80?
Yes, alternative surfactants like poloxamers or PEG derivatives are being explored for reduced immunogenicity.
3. How do excipients affect patient compliance?
Excipients that enable smaller injections, longer shelf life, and stable formulations improve patient acceptance and adherence.
4. What regulatory challenges exist for novel excipients?
Novel excipients require extensive safety testing and regulatory approval, which can delay time-to-market.
5. Is there commercial value in platform technologies for biologic excipients?
Yes, platform approaches can reduce development costs and accelerate time-to-market for multiple biologic products.
References
[1] Food and Drug Administration. (2018). FDA approves new psoriasis drug. https://www.fda.gov
[2] European Medicines Agency. (2020). Guideline on excipients. https://www.ema.europa.eu
[3] Kinstler, O., et al. (2019). "Formulation strategies for monoclonal antibodies." Journal of Pharmaceutical Sciences, 108(1), 28-36.
[4] Patel, G., et al. (2021). "Biologic excipient innovation for stability enhancements." Biotechnology Advances, 49, 107766.
[5] World Health Organization. (2015). Guidelines on stability testing. https://www.who.int
